Normal 0 21 false false false NL X-NONE X-NONE
References
1.
Scott LJ (2013) Gadobutrol: A review of its use for contrast-enhanced magnetic resonance imaging in adults and children.
Clin Drug Investig 33:303–314.
2.
Tweedle M,
Kanal E,
Muller R (2014) Considerations in the Selection of a New Gadolinium-Based Contrast Agent.
Appl Radiol
3.
Woolf DK,
Padhani AR,
Taylor NJ,
Gogbashian A,
Li SP,
Beresford MJ,
Ah-See ML,
Stirling J,
Collins DJ,
Makris A (2014) Assessing response in breast cancer with dynamic contrast-enhanced magnetic resonance imaging: Are signal intensity-time curves adequate? Breast Cancer Res Treat 147:335–343.
4.
Martens MH,
Subhani S,
Heijnen LA,
Lambregts DMJ,
Buijsen J,
Maas M,
Riedl RG,
Jeukens CRLPN,
Beets GL,
Kluza E,
Beets-Tan RGH (2015) Can perfusion MRI predict response to preoperative treatment in rectal cancer? Radiother Oncol 114:218–223.
5.
Dijkhoff RAP,
Maas M,
Martens MH,
Papanikolaou N,
Lambregts DMJ,
Beets GL,
Beets-Tan RGH (2017) Correlation between quantitative and semiquantitative parameters in DCE-MRI with a blood pool agent in rectal cancer: can semiquantitative parameters be used as a surrogate for quantitative parameters? Abdom Radiol 42:1342–1349.
6.
Intven M,
Reerink O,
Philippens MEP (2014) Dynamic contrast enhanced MR imaging for rectal cancer response assessment after neo-adjuvant chemoradiation.
J Magn Reson Imaging 0:n/a--n/a.
7.
Kuhl CK,
Mielcareck P,
Klaschik S,
Leutner C,
Wardelmann E,
Gieseke J,
Schild HH (1999) Dynamic Breast MR Imaging: Are Signal Intensity Time Course Data Useful for Differential Diagnosis of Enhancing Lesions? Radiology 211:101–110.
8.
Rosenkrantz AB,
Sabach A,
Babb JS,
Matza BW,
Taneja SS,
Deng FM (2013) Prostate cancer: Comparison of dynamic contrast-enhanced MRI techniques for localization of peripheral zone tumor.
Am J Roentgenol 201:471–478.
9.
Schipper R-J,
Smidt ML,
van Roozendaal LM,
Castro CJG,
de Vries B,
Heuts EM,
Keymeulen KBMI,
Wildberger JE,
Lobbes MBI,
Beets-Tan RGH (2013) Noninvasive nodal staging in patients with breast cancer using gadofosveset-enhanced magnetic resonance imaging: a feasibility study.
Invest Radiol 48:134–9.
10.
Bannas P,
Bookwalter CA,
Ziemlewicz T,
Motosugi U,
Munoz del Rio A,
Potretzke TA,
Nagle SK,
Reeder SB (2017) Combined gadoxetic acid and gadofosveset enhanced liver MRI for detection and characterization of liver metastases.
Eur Radiol 27:32–40.
11.
Puig J,
Blasco G,
Essig M,
Daunis-I-Estadella J,
Laguillo G,
Quiles AM,
Remollo S,
Bergmann K,
Joly C,
Bernado L,
S??nchez-Gonz??lez J,
Pedraza S (2013) Albumin-binding MR blood pool contrast agent improves diagnostic performance in human brain tumour: Comparison of two contrast agents for glioblastoma.
Eur Radiol 23:1093–1101.
12.
Maki JH,
Wang M,
Wilson GJ,
Shutske MG,
Leiner T (2009) Highly accelerated first-pass contrast-enhanced magnetic resonance angiography of the peripheral vasculature: Comparison of gadofosveset trisodium with gadopentetate dimeglumine contrast agents.
J Magn Reson Imaging 30:1085–1092.
13.
Richardson OC,
Bane O,
Scott MLJ,
Tanner SF,
Waterton JC,
Sourbron SP,
Carroll TJ,
Buckley DL (2015) Gadofosveset-based biomarker of tissue albumin concentration: Technical validation in vitro and feasibility in vivo.
Magn Reson Med 73:244–253.
14.
Lobbes MB,
Miserus RJ,
Heeneman S,
Passos VL,
Mutsaers PH,
Debernardi N,
Misselwitz B,
Post M,
Daemen MJ,
van Engelshoven JM,
Leiner T,
Kooi ME (2009) Atherosclerosis: contrast-enhanced MR imaging of vessel wall in rabbit model--comparison of gadofosveset and gadopentetate dimeglumine.
Radiology 250:682–691.
15.
Lambregts DMJ,
Beets GL,
Maas M,
Kessels AGH,
Bakers FCH,
Cappendijk VC,
Engelen SME,
Lahaye MJ,
de Bruïne AP,
Lammering G,
Leiner T,
Verwoerd JL,
Wildberger JE,
Beets-Tan RGH (2011) Accuracy of gadofosveset-enhanced MRI for nodal staging and restaging in rectal cancer.
Ann Surg 253:539–545.
16.
Port M,
Corot C,
Violas X,
Robert P,
Raynal I,
Gagneur G (2005) How to compare the efficiency of albumin-bound and nonalbumin-bound contrast agents in vivo: the concept of dynamic relaxivity.
Invest Radiol 40:565–73.